Big Gain For Translate Bio, Inc.
Translate Bio, Inc. (TBIO:NASDAQ) soared at $2.93, a gain of 117%. On Wed, Sep 18, 2024, TBIO:NASDAQ touched a New 2-Week Low of $1.36. The stock appeared on our News Catalysts scanner on Tue, Sep 10, 2024 at 07:23 PM in the 'INVESTOR UPDATE' category. From Wed, Sep 04, 2024, the stock recorded 30.00% Up Days and 45.45% Green Days
The stock spiked on Fri, Aug 02, 2024 at $6.17 with a volume of 2M+.
About Translate Bio, Inc. (TBIO:NASDAQ)
Translate Bio Inc is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, for the treatment of cystic fibrosis (CF) and MRT5201, for the treatment of ornithine transcarbamylase (OTC) deficiency.
Top 10 Gainers:
- Signing Day Sports Inc. (SGN:NYSEMKT), 308.01%
- Garden Stage Limited (GSIW:NASDAQ), 248%
- Zeo Energy Corp Cl A (ZEO:NASDAQ), 122.22%
- Translate Bio, Inc. (TBIO:NASDAQ), 117.04%
- Neo-Concept International Group Holdings Limited (NCI:NASDAQ), 71.6%
- Venus Concept Inc. (VERO:NASDAQ), 71.14%
- Edgewise Therapeutics Inc. (EWTX:NASDAQ), 54.69%
- Rezolve AI Limited (RZLV:NASDAQ), 47.37%
- Achilles Therapeutics plc (ACHL:NASDAQ), 35.74%
- Flora Growth Corp. (FLGC:NASDAQ), 35.24%